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Abstract
Background
There is growing concern that racial and ethnic minority communities around the world are
experiencing a disproportionate burden of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19). We investigated racial
and ethnic disparities in patterns of COVID-19 testing (i.e., who received testing and who
tested positive) and subsequent mortality in the largest integrated healthcare system in the
United States.
Methods and findings
This retrospective cohort study included 5,834,543 individuals receiving care in the US
Department of Veterans Affairs; most (91%) were men, 74% were non-Hispanic White
(White), 19% were non-Hispanic Black (Black), and 7% were Hispanic. We evaluated
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associations between race/ethnicity and receipt of COVID-19 testing, a positive test result,
and 30-day mortality, with multivariable adjustment for a wide range of demographic and
clinical characteristics including comorbid conditions, health behaviors, medication history,
site of care, and urban versus rural residence. Between February 8 and July 22, 2020,
254,595 individuals were tested for COVID-19, of whom 16,317 tested positive and 1,057
died. Black individuals were more likely to be tested (rate per 1,000 individuals: 60.0, 95%
CI 59.6–60.5) than Hispanic (52.7, 95% CI 52.1–53.4) and White individuals (38.6, 95% CI
38.4–38.7). While individuals from minority backgrounds were more likely to test positive
(Black versus White: odds ratio [OR] 1.93, 95% CI 1.85–2.01, p < 0.001; Hispanic versus
White: OR 1.84, 95% CI 1.74–1.94, p < 0.001), 30-day mortality did not differ by race/ethnic-
ity (Black versus White: OR 0.97, 95% CI 0.80–1.17, p = 0.74; Hispanic versus White: OR
0.99, 95% CI 0.73–1.34, p = 0.94). The disparity between Black and White individuals in
testing positive for COVID-19 was stronger in the Midwest (OR 2.66, 95% CI 2.41–2.95, p <
0.001) than the West (OR 1.24, 95% CI 1.11–1.39, p < 0.001). The disparity in testing posi-
tive for COVID-19 between Hispanic and White individuals was consistent across region,
calendar time, and outbreak pattern. Study limitations include underrepresentation of
women and a lack of detailed information on social determinants of health.
Conclusions
In this nationwide study, we found that Black and Hispanic individuals are experiencing an
excess burden of SARS-CoV-2 infection not entirely explained by underlying medical condi-
tions or where they live or receive care. There is an urgent need to proactively tailor strate-
gies to contain and prevent further outbreaks in racial and ethnic minority communities.
Author summary
Why was this study done?
• There is growing concern that racial and ethnic minority communities around the
world are experiencing a disproportionate burden of morbidity and mortality from
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
or coronavirus disease 2019 (COVID-19).
• Most studies investigating racial and ethnic disparities to date have focused on those
who tested positive for SARS-CoV-2 or hospitalized patients.
• No single study to our knowledge has yet investigated racial and ethnic disparities in
testing patterns (i.e., who received testing and who tested positive) as well as COVID-19
outcomes in a nationwide cohort with adequate adjustment for potential confounders.
What did the researchers do and find?
• We used electronic health records from the largest integrated healthcare system in the
US to investigate racial and ethnic disparities in testing and subsequent COVID-19
mortality.
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• Non-Hispanic Black and Hispanic individuals were twice as likely as non-Hispanic
White individuals to test positive for COVID-19, even after accounting for other demo-
graphics, geographic location, and underlying health conditions.
• The racial disparity between Black and White individuals in testing positive for
COVID-19 slightly decreased over the study period, and was highest in the Midwest
compared to all other regions. The ethnic disparity between Hispanic and White indi-
viduals in testing positive for COVID-19 was consistent across time, geographic region,
and outbreak pattern; the disparity was consistently observed across all strata.
• Among those who tested positive for COVID-19, there was no observed difference in
30-day mortality by race/ethnicity group.
What do these findings mean?
• Our findings highlight the urgent need for improved strategies to contain and prevent
further outbreaks in racial and ethnic minority communities.
Introduction
The United States has the highest number of reported symptomatic severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infections and related deaths in the world, accounting
for one-fourth of global totals as of July 22, 2020 [1]. There is growing concern that racial and
ethnic minority communities are experiencing a disproportionate burden of morbidity and
mortality from symptomatic SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19)
[2–8]. One statewide study investigating racial disparities followed 3,481 COVID-19 cases in
Louisiana and found that non-Hispanic Black individuals represented 77% of hospitalizations
and 71% of deaths despite only making up 31% of the total source population [9]. Thus, the
potential for racial and ethnic disparities in COVID-19 have been deemed an urgent public
health research priority [10]. However, most studies investigating racial and ethnic disparities
have focused on hospitalized patients or have not characterized who received testing or tested
positive for COVID-19 [9,11–15]. Given that COVID-19 testing was not performed at ran-
dom, particularly in the early phases of the pandemic, evaluating underlying testing patterns
and changes over time may provide important context for interpreting findings from models
of COVID-19 outcomes. In addition, it is not yet known whether disparities in COVID-19
infection or severe outcomes are explained, at least in part, by differences in underlying health
conditions, smoking and alcohol use, geographic location, or urban versus rural residence—
essential information if we are to design effective interventions.
The electronic health record database of the Department of Veterans Affairs (VA) offers the
single largest nationwide data resource available with the necessary information on system-
wide testing and detailed medical histories to examine racial and ethnic disparities in the US.
We evaluated associations between race/ethnicity and receipt of COVID-19 testing, a positive
test result, and 30-day mortality, conditioning each analysis on the previous outcome and
accounting for a wide range of demographic and clinical characteristics through July 22, 2020.
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Methods
Data source
The VA is the largest integrated healthcare system in the US and comprises over 1,200 points of
care (i.e., sites) nationwide including hospitals, medical centers, and community outpatient
clinics. All care is recorded in an electronic health record with daily uploads into the VA Corpo-
rate Data Warehouse. Available data include demographics, outpatient and inpatient encoun-
ters, diagnoses, smoking and alcohol health behaviors, and pharmacy dispensing records.
This study was approved by the institutional review boards of VA Connecticut Healthcare
System and Yale University. It has been granted a waiver of informed consent and is Health
Insurance Portability and Accountability Act compliant. The analyses herein were not pre-
specified in a formal protocol, rather were informed by hypotheses drawn from prior work
[16]. This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines (S1 STROBE Checklist).
Sample, follow-up, and outcomes
All individuals in clinical care (defined as having at least 1 clinical encounter between January
1, 2018, and December 31, 2019, and alive as of January 1, 2020) were included in this analysis.
We identified individuals tested for COVID-19 from the date of the VA’s first recorded test,
on February 8, 2020, through July 22, 2020, by using text searching of laboratory results con-
taining terms consistent with SARS-CoV-2 or COVID-19. Nearly all tests utilized nasopharyn-
geal swabs; 1% were from other sources. Testing was performed in VA, state public health, and
commercial reference laboratories using FDA Emergency Use Authorization–approved
SARS-CoV-2 assays. We did not include antibody tests in this analysis.
If an individual had more than 1 test and all were negative, we selected the date of the first
negative test; otherwise we used the date of the first positive test. Baseline for individuals tested
for COVID-19 was defined as the date of specimen collection unless testing occurred during
hospitalization, in which case baseline was defined as the date of admission. If the admission
began more than 14 days prior to testing, which may indicate hospital-acquired infection, we
set baseline to 14 days prior to testing to better capture health status prior to SARS-CoV-2
infection. We examined 3 outcomes: (1) receipt of COVID-19 testing among all in care, (2)
receipt of a positive test result among individuals tested for COVID-19, and (3) 30-day mortal-
ity among COVID-19 cases. Deaths were ascertained using inpatient records and VA death
registry data to capture deaths outside of hospitalization. The choice of 30-day mortality as the
outcome was guided by the distribution of mortality events by time since testing positive for
COVID-19 (50th, 75th, 90th percentile time to death: 12, 20, 30 days) and to allow for suffi-
cient follow-up within the study period. While there were some deaths beyond 30 days after
testing positive for COVID-19, we were less certain that these deaths could be attributed to
COVID-19. Given the low number of deaths after 30 days, 30-day mortality may be a reason-
able proxy for case fatality rate. However, until longer follow-up has accrued, it remains to be
seen whether those who develop symptomatic COVID-19 experience longer term excess
mortality.
Variables
The primary exposure variable was self-reported race/ethnicity (non-Hispanic White [White],
non-Hispanic Black [Black], and Hispanic). Analyses of other racial and ethnic backgrounds
were underpowered at the time of this analysis, and therefore individuals who self-reported
race/ethnicity other than White, Black, or Hispanic were excluded from the study population.
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We selected demographic and clinical characteristics that have been evaluated in prior
COVID-19 reports and could potentially mediate or explain racial/ethnic disparities in
COVID-19 positivity and mortality. Demographics included age at baseline, sex, and rural/
urban residence. Rural/urban residence was defined using geographic information system
coding based upon established criteria [17]. Clinical characteristics were based on diagnostic
codes for asthma, any cancer, chronic obstructive pulmonary disease (COPD), chronic kidney
disease, diabetes mellitus, hypertension, liver disease, vascular disease, and alcohol use disorder
(definitions provided in S1 Table). Presence of conditions was determined by 1 inpatient or 2
outpatient diagnoses in the 2 years prior to baseline, except for cancer, which was considered
present if diagnosed ever prior to baseline. Diagnoses made in the 7 days prior to baseline
were not included. We used a validated algorithm to capture smoking status [18] and alcohol
consumption [19]. We collected pharmacy fills for angiotensin converting enzyme (ACE)
inhibitors and angiotensin II receptor blockers (ARBs) and identified individuals with active
prescriptions in the 30 days prior to baseline. Missing data for smoking and alcohol consump-
tion affected only 5% of individuals included in multivariable models; thus, complete case
analysis was performed.
We also created variables to assess potential variation in racial/ethnic disparities by calendar
time, region, and outbreak pattern. We split the population into 3 groups based on date of
COVID-19 test: February 8 to April 21, April 22 to June 21, and June 22 to July 22. States were
grouped into 4 US Census regions (i.e., West, South, Midwest, and Northeast) [20]. Outbreak
patterns were based on site-level percentage of positive tests per month among sites with at
least 100 positive COVID-19 tests: early (�10% in March or April), late (�10% in June or
July), resurgent (�10% in March or April and June or July), steady (<10% in all months), and
other (sites with <100 positive tests).
Statistical analysis
We calculated COVID-19 testing rate per 1,000 individuals in care and Clopper–Pearson 95%
confidence intervals (CIs) by race/ethnicity category. Among those tested for COVID-19, we
calculated percent testing positive and 95% CIs by race/ethnicity category. Logistic regression
models were used to estimate associations between race/ethnicity and COVID-19 positivity
and mortality, adjusting for sets of potential mediators of such disparities, moving from more
distal to more proximate determinants of health. Age-adjusted models included race/ethnicity
and age. Demographic-adjusted models additionally included sex and rural/urban residence,
and were conditioned on site of care. Fully adjusted models additionally included all clinical
covariates, substance use, and medication history. We report the estimates of each individual
adjustment as well as those arising from a fully adjusted model. We repeated this modeling
strategy to estimate odds ratios (ORs) and 95% CIs between race/ethnicity and 30-day mortal-
ity among those who tested positive for COVID-19 on or prior to June 21, 2020, to allow all
individuals 30 days of follow-up. We evaluated variation in racial/ethnic disparities in testing
positive for COVID-19 by stratifying the fully adjusted model by calendar time, geographic
region, and site-level outbreak pattern. In sensitivity analyses, we restricted ascertainment of
30-day mortality to only include inpatient deaths to test the robustness of the associations
found in the primary models. Analyses were performed using SAS version 9.4 (SAS Institute,
Cary, NC, US). R version 3.6.3 was used to map COVID-19 cases nationwide.
Results
There were 5,834,543 individuals in care prior to the COVID-19 pandemic. Most (91%) were
men, 74% were White, 19% were Black, and 7% were Hispanic (Table 1). Age distributions
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were similar by race/ethnicity, and age ranged from 20 to 105 years, with 24% less than 50
years, 35% 50–69 years, 28% 70–79 years, and 13%�70 years of age. Of these, 254,595 (43.6
per 1,000 individuals in care) were tested for COVID-19, of whom 65% were White, 26% were
Black, and 9% were Hispanic. There were 16,317 (6.4%) individuals who tested positive for
COVID-19 between February 8 and July 22, 2020, of whom 44% were White, 40% were Black,
and 16% were Hispanic. While 66% of all individuals in care resided in urban areas, 76% of
those tested and 87% of those testing positive for COVID-19 resided in urban areas. The
Table 1. Characteristics of all individuals who were in care, were tested, tested positive, and died as of July 22, 2020.
Characteristic In care Tested Tested positive Died
Number Column percent Number Column percent Number Column percent Number Column percent
Sample size, n (%) 5,834,543 100.0% 254,595 100.0% 16,317 100.0% 1,057 100.0%
Race/ethnicity
White 4,309,613 73.9% 166,213 65.3% 7,159 43.9% 525 49.7%
Black 1,089,883 18.7% 65,441 25.7% 6,589 40.4% 433 41.0%
Hispanic 435,047 7.5% 22,941 9.0% 2,569 15.7% 99 9.4%
Age, years
20–39 842,948 14.4% 28,695 11.3% 2,719 16.7% 1 0.1%
40–49 577,135 9.9% 23,422 9.2% 1,879 11.5% 11 1.0%
50–59 840,779 14.4% 42,877 16.8% 3,071 18.8% 52 4.9%
60–69 1,210,960 20.8% 65,308 25.7% 3,705 22.7% 192 18.2%
70–79 1,620,765 27.8% 71,005 27.9% 3,528 21.6% 411 38.9%
�80 741,956 12.7% 23,288 9.1% 1,415 8.7% 390 36.9%
Sex
Female 522,738 9.0% 27,475 10.8% 1,694 10.4% 24 2.3%
Male 5,311,805 91.0% 227,120 89.2% 14,623 89.6% 1,033 97.7%
Residence
Rural 2,002,299 34.3% 61,845 24.3% 2,169 13.3% 121 11.4%
Urban 3,832,244 65.7% 192,750 75.7% 14,148 86.7% 936 88.6%
Date of COVID-19 test
Feb 8–Apr 21 n/a n/a 38,311 15.0% 4,246 26.0% 582 55.1%
Apr 22–Jun 21 n/a n/a 120,313 47.3% 4,379 26.8% 349 33.0%
Jun 22–Jul 22 n/a n/a 95,971 37.7% 7,692 47.1% 126 11.9%
Region
West 1,162,263 19.9% 56,303 22.1% 2,863 17.5% 128 12.1%
South 2,697,047 46.2% 113,594 44.6% 8,324 51.0% 371 35.1%
Midwest 1,235,865 21.2% 50,796 20.0% 2,464 15.1% 172 16.3%
Northeast 737,135 12.6% 33,902 13.3% 2,666 16.3% 386 36.5%
Outbreak pattern
Early 795,442 13.6% 44,786 17.6% 4,453 27.3% 523 49.5%
Late 1,201,717 20.6% 49,454 19.4% 4,866 29.8% 139 13.2%
Resurgent 397,372 6.8% 16,892 6.6% 1,564 9.6% 67 6.3%
Steady 1,697,326 29.1% 84,745 33.3% 3,690 22.6% 214 20.2%
Other 1,742,686 29.9% 58,718 23.1% 1,744 10.7% 114 10.8%
Region based on US Census groupings. Outbreak pattern based on site-level percentage of positive tests per month among sites with at least 100 positive COVID-19
tests: early (�10% in March or April), late (�10% in June or July), resurgent (�10% in March or April and June or July), steady (<10% in all months), or other (sites
with <100 positive tests).
COVID-19, coronavirus disease 2019; n/a, not applicable.
https://doi.org/10.1371/journal.pmed.1003379.t001
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geographic distribution of COVID-19 cases in the VA was similar to the pattern of known hot-
spots in the general population, including in the Northeast, South, and some Midwestern states
(Fig 1). Several VA sites with the highest proportion of positive COVID-19 tests also per-
formed a higher volume of tests and had the highest proportion of Black individuals in care,
including New York City, New Orleans, and Chicago (Fig 1).
Rate of testing and testing positive
Of the 254,595 patients tested for COVID-19, 73% received 1 test, 16% received 2 tests, 6%
received 3 tests, and the remaining 5% received 4 or more tests. After reducing to 1 test per
patient as described in Methods above, testing rates for COVID-19 were higher among Black
(rate per 1,000 individuals: 60.0, 95% CI 59.6–60.5) and Hispanic individuals (52.7, 95% CI
52.1–53.4) compared to White individuals (38.6, 95% CI 38.4–38.7). Testing rates also varied
by age, sex, rural/urban residence, region, and outbreak pattern (Table 2).
Among individuals tested for COVID-19, the proportion with a positive test varied by race/
ethnicity (Table 2); 4.4% (95% CI 4.3%–4.5%) of White, 10.2% (95% CI 10.0%–10.4%) of
Black, and 11.4% (95% CI 11.0%–11.9%) of Hispanic individuals tested positive for COVID-
19. For White and Black individuals, the proportion of positive COVID-19 tests was highest at
ages under 60 years and at or over 80 years. For Hispanic individuals, the proportion of posi-
tive test results was highest among lower age groups (15.6%, 95% CI 14.6%–16.6%, for 20–39
years) and continuously decreased with increasing age.
Regression modeling of testing positive
Unadjusted associations between race/ethnicity and testing positive for COVID-19 yielded OR
2.49 (95% CI 2.40–2.58, p< 0.001) for Black and OR 2.80 (95% CI 2.67–2.94, p< 0.001) for
Hispanic individuals compared to White individuals. After adjusting for age, the odds of test-
ing positive did not change among Black individuals (OR 2.48, 95% CI 2.40–2.57, p< 0.001)
Fig 1. Distribution of 16,317 laboratory-confirmed COVID-19 cases in the US Department of Veterans Affairs as of July 22, 2020. (a) Distribution of all
COVID-19 laboratory-confirmed cases in the US Department of Veterans Affairs between February 8 and July 22, 2020, included in the current study. (b)
Proportion of positive COVID-19 test results by the proportion of Black individuals in care by site. Map created using R library USMAP (v0.5.0) and RStudio
(v3.6.3). COVID-19, coronavirus disease 2019.
https://doi.org/10.1371/journal.pmed.1003379.g001
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and somewhat attenuated among Hispanic individuals (OR 2.56, 95% CI 2.44–2.69, p< 0.001)
(Table 3). These associations further attenuated after additionally accounting for sex, rural/
urban residence, and site of care among Black (OR 1.92, 95% CI 1.85–2.00, p< 0.001) and His-
panic individuals (OR 1.96, 95% CI 1.86–2.07, p< 0.001). These estimates were robust to any
individual (S2 Table) or combined adjustment for comorbidities, substance use, and medica-
tion history. In fully adjusted models, Black (OR 1.93, 95% CI 1.85–2.01, p< 0.001) and His-
panic (OR 1.84, 95% CI 1.74–1.94, p< 0.001) individuals remained at increased odds of
testing positive for COVID-19 (Fig 2).
The disparity in testing positive for COVID-19 between Black and White individuals
decreased between the calendar periods February 8–April 21 (OR 2.16, 95% CI 1.98–2.36, p<
0.001) and June 22–July 22 (OR 1.74, 95% CI 1.64–1.85, p< 0.001) (Fig 3). By region, the
Table 2. COVID-19 testing by race/ethnicity among all individuals in care as of July 22, 2020.
Characteristic Testing rate per 1,000 (95% CI) Percent testing positive (95% CI)
White
(n = 4,309,613)
Black
(n = 1,089,883)
Hispanic
(n = 435,047)
White
(n = 166,213)
Black
(n = 65,441)
Hispanic
(n = 22,941)
All individuals 38.6 (38.4–38.7) 60.0 (59.6–60.5) 52.7 (52.1–53.4) 4.4 (4.3–4.5) 10.2 (10.0–10.4) 11.4 (11.0–11.9)
Age, years
20–39 32.0 (31.5–32.4) 39.5 (38.5–40.4) 44.1 (42.9–45.2) 6.1 (5.8–6.5) 13.8 (13.0–14.7) 15.6 (14.6–16.6)
40–49 38.1 (37.5–38.7) 45.9 (44.9–47.0) 49.8 (48.2–51.6) 4.8 (4.5–5.2) 11.9 (11.1–12.7) 13.6 (12.4–14.8)
50–59 47.5 (46.9–48.0) 60.4 (59.5–61.3) 59.8 (58.0–61.7) 4.6 (4.3–4.9) 10.4 (10.0–11.0) 11.2 (10.2–12.3)
60–69 48.1 (47.7–48.6) 71.1 (70.2–72.0) 61.9 (60.2–63.6) 3.7 (3.5–3.9) 8.6 (8.2–9.0) 9.1 (8.3–10)
70–79 38.4 (38.1–38.7) 67.9 (66.7–69.1) 54.4 (52.8–56.0) 3.7 (3.6–3.9) 9.1 (8.6–9.7) 8.1 (7.3–8.9)
�80 25.5 (25.1–25.9) 69.7 (67.6–71.9) 53.0 (50.6–55.4) 4.9 (4.6–5.2) 10.9 (10.0–12.0) 6.8 (5.7–8.0)
Sex
Female 49.9 (49.1–50.7) 56.0 (54.9–57.1) 57.7 (55.6–59.9) 3.9 (3.6–4.2) 9.0 (8.4–9.6) 9.0 (7.9–10.2)
Male 37.7 (37.5–37.9) 60.8 (60.3–61.3) 52.1 (51.4–52.8) 4.3 (4.2–4.5) 10.3 (10.0–10.5) 11.5 (11.1–11.9)
Residence
Rural 30.1 (29.9–30.4) 39.8 (38.9–40.7) 32.6 (31.3–34.0) 2.6 (2.5–2.8) 8.8 (8.1–9.5) 7.9 (6.8–9.1)
Urban 44.4 (44.1–44.6) 64.0 (63.5–64.5) 56.5 (55.7–57.2) 5.1 (5.0–5.2) 10.2 (10.0–10.5) 11.5 (11.1–12.0)
Date of COVID-19 test
Feb 8–Apr 21 n/a n/a n/a 6.7 (6.4–7.0) 19.4 (18.7–20.1) 13.9 (12.7–15.0)
Apr 22–Jun 21 n/a n/a n/a 2.6 (2.5–2.7) 5.8 (5.5–6.1) 5.5 (5.1–6.0)
Jun 22–Jul 22 n/a n/a n/a 5.6 (5.4–5.8) 11.2 (10.8–11.6) 16.0 (15.2–16.7)
Region
West 43.9 (43.5–44.4) 72.9 (71.4–74.3) 55.5 (54.4–56.7) 4.2 (4.0–4.4) 5.5 (5.1–6.0) 9.0 (8.4–9.6)
South 37.5 (37.2–37.8) 51.9 (51.4–52.4) 46.9 (46.1–47.8) 4.7 (4.5–4.9) 10.4 (10.1–10.7) 12.4 (11.8–13.0)
Midwest 36.4 (36.1–36.8) 72.1 (70.8–73.4) 52.4 (49.7–55.1) 3.2 (3.0–3.4) 10.5 (9.9–11.1) 8.3 (6.9–9.8)
Northeast 37.6 (37.1–38.1) 89.6 (87.7–91.5) 81.0 (78.1–83.9) 5.3 (5.0–5.6) 13.0 (12.3–13.8) 14.6 (13.3–16.0)
Outbreak pattern
Early 43.8 (43.3–44.4) 84.4 (83.2–85.7) 73.3 (71.1–75.6) 6.4 (6.1–6.7) 14.3 (13.8–14.9) 13.5 (12.4–14.7)
Late 37.2 (36.8–37.6) 48.4 (47.6–49.2) 50.0 (48.9–51.1) 7.1 (6.8–7.4) 11.4 (10.9–11.9) 17.3 (16.5–18.2)
Resurgent 34.4 (33.6–35.2) 51.3 (50.3–52.4) 50.2 (47.4–53.2) 5.8 (5.2–6.3) 11.4 (10.8–12.1) 14.2 (12.2–16.4)
Steady 45.5 (45.2–45.9) 65.8 (65.0–66.7) 57.4 (55.9–58.9) 3.3 (3.2–3.5) 6.4 (6.1–6.8) 7.8 (7.1–8.5)
Other 31.9 (31.6–32.2) 47.0 (45.9–48.2) 44.0 (42.8–45.1) 2.5 (2.4–2.7) 5.8 (5.2–6.4) 3.5 (3.0–4.1)
Region based on US Census groupings. Outbreak pattern based on site-level percentage of positive tests per month among sites with at least 100 positive COVID-19
tests: early (�10% in March or April), late (�10% in June or July), resurgent (�10% in March or April and June or July), steady (<10% in all months), or other (sites
with <100 positive tests).
CI, confidence interval; COVID-19, coronavirus disease 2019; n/a, not applicable.
https://doi.org/10.1371/journal.pmed.1003379.t002
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disparity between Black and White individuals was highest in the Midwest (OR 2.66, 95% CI
2.41–2.95, p< 0.001) than any other region, and lowest in the West (OR 1.24, 95% CI 1.11–
1.39, p< 0.001). By outbreak pattern, the disparity between Black and White individuals was
highest at VA sites that experienced an early (OR 2.11, 95% CI 1.95–2.28, p< 0.001) or resur-
gent (OR 2.06, 95% CI 1.81–2.35, p< 0.001) outbreak and lowest at VA sites that experienced
a late outbreak (OR 1.66, 95% CI 1.54–1.80, p< 0.001). In contrast, there was no variation
observed in the disparity between Hispanic and White individuals by calendar time, region, or
outbreak pattern.
Regression modeling of 30-day mortality
There were 8,625 individuals who tested positive for COVID-19 on or before June 21, 2020, of
whom 931 (457 [49%] White; 392 [42%] Black; and 82 [9%] Hispanic) died within 30 days.
Unadjusted associations between race/ethnicity and mortality within 30 days of a positive test
yielded OR 0.76 (95% CI 0.66–0.88, p< 0.001) for Black and OR 0.60 (95% CI 0.47–0.77, p<
Table 3. Associations with testing positive and subsequent 30-day mortality, February 8 to July 22, 2020.
Characteristic Positive test result among tested (n/N = 16,317/254,595) 30-day mortality among cases� (n/N = 931/8,625)
Age-adjusted Demographic-
adjusteda
Fully adjustedb Age-adjusted Demographic-
adjusteda
Fully adjustedb
OR (95%
CI)
p-Value OR (95%
CI)
p-Value OR (95%
CI)
p-Value OR (95%
CI)
p-Value OR (95%
CI)
p-Value OR (95%
CI)
p-Value
Race/ethnicity
White ref ref ref ref ref ref
Black 2.48 (2.40–
2.57)
<0.001 1.92 (1.85–
2.00)
<0.001 1.93 (1.85–
2.01)
<0.001 1.08 (0.93–
1.26)
0.32 1.02 (0.84–
1.22)
0.87 0.97 (0.80–
1.17)
0.74
Hispanic 2.56 (2.44–
2.69)
<0.001 1.96 (1.86–
2.07)
<0.001 1.84 (1.74–
1.94)
<0.001 1.11 (0.85–
1.44)
0.46 0.98 (0.72–
1.31)
0.87 0.99 (0.73–
1.34)
0.94
Age, years
20–39 1.74 (1.65–
1.83)
<0.001 1.75 (1.66–
1.85)
<0.001 1.58 (1.49–
1.68)
<0.001
40–49 1.45 (1.37–
1.54)
<0.001 1.44 (1.36–
1.53)
<0.001 1.28 (1.20–
1.36)
<0.001
50–59 1.28 (1.22–
1.35)
<0.001 1.27 (1.20–
1.33)
<0.001 1.16 (1.10–
1.22)
<0.001 0.18 (0.13–
0.25)c
<0.001 0.20 (0.15–
0.27)c
<0.001 0.27 (0.19–
0.37)c
<0.001
60–69 ref ref ref ref ref ref
70–79 0.87 (0.83–
0.91)
<0.001 1.02 (0.97–
1.07)
0.41 0.93 (0.89–
0.98)
0.01 2.43 (2.00–
2.95)
<0.001 2.34 (1.91–
2.86)
<0.001 2.02 (1.64–
2.48)
<0.001
�80 1.08 (1.01–
1.15)
0.02 1.28 (1.20–
1.36)
<0.001 1.08 (1.01–
1.16)
0.02 6.39 (5.21–
7.85)
<0.001 5.92 (4.78–
7.34)
<0.001 4.59 (3.64–
5.78)
<0.001
Sex, male versus female 1.27 (1.20–
1.34)
<0.001 1.38 (1.31–
1.46)
<0.001 1.58 (1.49–
1.67)
<0.001 1.59 (1.00–
2.53)
0.048 1.53 (0.96–
2.45)
0.07 1.48 (0.92–
2.36)
0.11
Residence, urban
versus rural
2.10 (2.00–
2.20)
<0.001 1.39 (1.32–
1.46)
<0.001 1.39 (1.32–
1.46)
<0.001 1.16 (0.92–
1.47)
0.22 1.06 (0.81–
1.39)
0.68 1.03 (0.79–
1.36)
0.81
�Models of 30-day mortality limited to cases testing positive for COVID-19 on or before June 21, 2020, to allow 30 days of follow-up.
aAdditionally adjusted for sex and rural/urban residence, and conditioned on site of care.
bAdditionally adjusted for baseline comorbidity (asthma, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, liver
disease, vascular disease), substance use (alcohol consumption, alcohol use disorder, smoking status), and medication history (angiotensin converting enzyme inhibitor,
angiotensin II receptor blocker).
cOR for age 20–59 years. Low number of mortality events in age groups 20–39 and 40–49 years, thus grouped with age group 50–59 years.
CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003379.t003
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0.001) for Hispanic individuals compared to White individuals. This association was not
observed after adjusting for age among Black (OR 1.08, 95% CI 0.93–1.26, p = 0.32) and His-
panic individuals (OR 1.11, 95% CI 0.85–1.44, p = 0.46) (Table 3). The null association was
robust to any further adjustment (Fig 2). Most deaths (n = 603, 65%) occurred in hospital. In
sensitivity analyses, results from a model of 30-day mortality restricted to inpatient deaths did
not alter the conclusions from the primary analyses (OR 1.12, 95% CI 0.90–1.40, p = 0.32,
among Black individuals; OR 1.08, 95% CI 0.76–1.54, p = 0.65, among Hispanic individuals).
Discussion
This study examined racial and ethnic disparities in testing and subsequent COVID-19 mor-
tality among approximately 6 million individuals receiving care in the US. We found that
Black and Hispanic individuals were more likely to be tested and to test positive for COVID-
19 than White individuals, even after comprehensive adjustment for underlying health condi-
tions, other demographics, and geographic location. Among the variables assessed in this
study, age, rural/urban residence, and site of care explained more of the racial/ethnic disparity
in testing positive for COVID-19 than comorbidities, substance use, or medication history.
While the disparity between Black and White individuals decreased over time, the disparity
was strongest in the Midwest and at VA sites that experienced an early or resurgent outbreak.
There was no variation observed in the disparity between Hispanic and White individuals by
calendar time, region, or outbreak pattern. While individuals from minority backgrounds
Fig 2. Adjusted associations of demographic characteristics with testing positive for COVID-19 and subsequent 30-day mortality as of July 22, 2020. (a)
Positive test result among tested; (b) 30-day mortality among cases. Both models were conditioned on site of care and adjusted for baseline comorbidity (asthma,
cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, liver disease, vascular disease), substance use (alcohol
consumption, alcohol use disorder, smoking status), and medication history (angiotensin converting enzyme inhibitor, angiotensin II receptor blocker). �Low
number of mortality events in age groups 20–39 and 40–49 thus grouped with 50–59. CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003379.g002
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appeared to experience excess burden of COVID-19, among those infected, there was no
observed difference in 30-day mortality by race/ethnicity group. The apparent racial/ethnic
disparity in mortality in unadjusted data was principally explained by differing age structures
between the populations.
Key strengths and limitations
This study elucidated racial and ethnic disparities in testing patterns of COVID-19 indepen-
dent of underlying health status and other key factors in a nationwide sample. Strengths of this
study included that it was based on well-annotated electronic health record data from a team
with decades of experience using VA data, enabling a rapid and reliable analysis of COVID-19
outcomes by race and ethnicity. This analysis utilized patients’ records from an entire health-
care system, which made it less prone to collider bias (i.e., non-random selection of individuals
into a study) than other COVID-19 studies limited to individuals testing positive or admitted
to hospital [21]. Unlike other nationwide healthcare systems, linkage to COVID-19 testing
data or outcomes was not required as the integrated nature of VA healthcare provided at over
1,200 sites allows all information to be stored in its Corporate Data Warehouse. We used vali-
dated algorithms to accurately extract information on and adjust models for a wide range of
clinical, behavioral, and geographic factors, with very little missingness in the data. The scale
Fig 3. Racial and ethnic disparities in testing positive for COVID-19, by calendar time, region, and outbreak pattern. (a) Black versus White individuals; (b)
Hispanic versus White individuals. All p< 0.001. Region based on US Census groupings. Outbreak pattern based on site-level percentage of positive tests per
month among sites with at least 100 positive COVID-19 tests: early (�10% in March or April), late (�10% in June or July), resurgent (�10% in March or April
and June or July), steady (<10% in all months), other (sites with<100 positive tests). Models were conditioned on site of care and adjusted for baseline
comorbidity (asthma, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, liver disease, vascular disease),
substance use (alcohol consumption, alcohol use disorder, smoking status), and medication history (angiotensin converting enzyme inhibitor, angiotensin II
receptor blocker). CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003379.g003
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of VA data also allowed us to assess the impact of COVID-19 separately across multiple racial
and ethnic minority groups; combining or limiting analyses to a single minority group would
have masked important differences between Black and Hispanic individuals. We continue to
monitor COVID-19 outcomes for individuals of other minority backgrounds and plan to fol-
low up these analyses when there are sufficient numbers for analysis.
While this analysis adds information, its limitations must be kept in mind. First, this study
was conducted on veterans currently receiving care in the VA, who are older and have a higher
prevalence of chronic health conditions and risk behaviors than the general US population
[22–24]. However, prior research has established that after adjusting for age, sex, race/ethnic-
ity, region, and rural/urban residence, all of which were included in this study, there is no dif-
ference in total disease burden between veterans and non-veterans [24]. Our key finding of no
observed racial disparity of COVID-19 mortality has also been shown in a smaller non-veteran
population [9]; thus, associations reported in this study are likely generalizable to the wider US
population. Second, while individuals in VA care represent a diversity of backgrounds, women
represented a small proportion of individuals in the sample. Thus, our analysis was not pow-
ered to assess interactions between sex and race/ethnicity. Third, beyond adjusting for rural/
urban location and site of testing, we were not able to explore likely social determinants of the
pronounced differential burden of COVID-19 among minority individuals. More detailed
information on nursing home residence and socioeconomic status (e.g., type of employment,
income, number of individuals in household) were unavailable or not consistently recorded in
VA data, as is the case in most other electronic health record data sources. Fourth, as is true
outside the VA, only a small proportion of individuals have been tested (~5%), and rates of
testing vary by site and within important subgroups. However, while initial testing was limited,
by mid-April the VA began testing all individuals admitted to hospital and before any inpa-
tient or outpatient procedures, even in those not suspected to have COVID-19. Our models
for testing positive should be cautiously interpreted as a proxy of odds of infection since those
with mild symptoms were unlikely to have received testing, particularly in the early stages of
the outbreak.
Findings in context
Our findings of racial and ethnic disparities in COVID-19 provide important distinctions
from previous reports in the US and other countries with ethnically diverse populations. To
our knowledge, one of the largest studies to date on racial disparities in COVID-19 outcomes
in the US followed 3,481 COVID-19 cases in the state of Louisiana and found that non-His-
panic Black individuals represented 77% of hospitalizations and 71% of deaths despite only
making up 31% of the total source population [9]. However, this study was based on patients
who tested positive for COVID-19 in a statewide healthcare system and was underpowered to
investigate ethnic minorities. We were able to expand the scope of this finding nationally and
to include Hispanic individuals. In the UK, which was the first country with a broadly ethni-
cally diverse population to experience a COVID-19 outbreak [25], a study of 17 million indi-
viduals showed that those from minority backgrounds had a substantially higher risk of
mortality from COVID-19, which was not fully explained by underlying health conditions or
social deprivation [26]. While our study also found racial and ethnic disparities, we found that
these disparities occurred primarily at a stage prior to hospitalization (i.e., testing positive for
COVID-19). We found no evidence of racial or ethnic disparities in 30-day mortality once
models were restricted to those who tested positive for COVID-19. Our findings may be an
underestimate of the US population risk as health disparities in the VA tend to be smaller than
in the private sector [27]. Nevertheless, at a population level the substantial excess burden of
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SARS-CoV-2 infection among Black and Hispanic individuals inevitably translates to excess
COVID-19 mortality in these communities.
We demonstrated that Black and Hispanic individuals were more likely to test positive than
their White counterparts even after accounting for underlying health conditions, other demo-
graphics, rural/urban residence, and site of care. Based on experience with the 1918 Spanish
flu and the 2009 H1N1 epidemic, public health experts have warned that racial and ethnic
minority populations may be at higher risk during infectious disease outbreaks due to underly-
ing health conditions, lower access to care, and socioeconomic conditions [28,29]. Notably,
our analysis found that underlying health conditions did not explain any of the disparity
between racial/ethnic groups in the odds of testing positive for COVID-19 or subsequent mor-
tality in models already accounting for demographics, principally age, rural/urban residence,
and VA site of care—essential information to help guide effective interventions. Prior reports
have also highlighted that members of racial and ethnic minorities are more likely to live in
densely populated areas or multigenerational households, and minority groups are overrepre-
sented in jails, prisons, and detention centers, all of which lead to reduced capacity to imple-
ment physical distancing [30–34]. Similarly, Black and Hispanic workers are more likely than
their White counterparts to be workers in essential industries, who continue to work outside
the home despite outbreaks in their communities, making them more prone to exposure and
therefore infection [34–36].
We found substantial variation in the disparity between Black and White individuals in
testing positive for COVID-19 by geographic region, with stronger disparity observed in the
Midwest than all other regions, and disparity most attenuated in the West. Further breakdown
of groups within the Black community (e.g., African American, Afro-Caribbean, African),
which could potentially reveal additional variation, is not captured in VA data. The observed
disparities may be due to differential social determinants of health between Black and White
individuals across regions. A US Census Bureau report showed that while racial residential
segregation has diminished over time nationally, communities in the Midwest remained less
integrated than in the West [37]. If community-level exposure is driving risk of SARS-CoV-2
infections, then the disparity in testing positive for COVID-19 may be lower in regions with
greater integration between White and Black residents, as is the case in the West. We also
found that the disparity between Black and White individuals in testing positive slightly
decreased over the study period and was highest at VA sites that experienced an early outbreak
of COVID-19. This finding may be partially explained by the increased attention on racial dis-
parities in COVID-19 in the media [3–5] that may have impacted behaviors like wearing face
coverings in public to reduce the spread of infection [38].
Interestingly, the ethnic disparity between Hispanic and White individuals in testing posi-
tive for COVID-19 was consistent across time, geographic region, and outbreak pattern; the
disparity was consistently observed across all strata. The lack of variation over time may be
explained, in part, by less nationwide media coverage and epidemiological investigations of
outbreaks of COVID-19 in Hispanic communities. Importantly, the Hispanic population in
the US comprises a wide array of ethnic communities (e.g., Mexican, Puerto Rican, Cuban).
However, these distinctions are not captured in VA data. The umbrella grouping may mask
any potential variation within such a heterogeneous population. Further research on the
impact of COVID-19 in Hispanic and Latinx communities is urgently needed.
Testing rates for COVID-19 in the VA were higher among Black and Hispanic individuals
compared to White individuals. Local reporting from metropolitan areas with large minority
populations, including New York City [39] and Chicago [40], has highlighted the dispropor-
tionate impact of COVID-19 in minority communities. We showed that VA facilities in these
cities and others around the country that conducted the highest number of COVID-19 tests
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also had the highest proportion of Black individuals in care. There were also differences in the
rate of COVID-19 testing and the proportion testing positive by age, sex, and type of residence
across race/ethnicity groups. These findings demonstrate the need for epidemiological investi-
gations to characterize testing patterns in the underlying population as they provide important
context for interpretations of models of COVID-19 outcomes. To our knowledge, the largest
medical record study to date analyzed COVID-19-related mortality in a population of 17 mil-
lion residents in the UK, the vast majority of whom never tested for COVID-19 [26]. While
the authors identified ethnic disparities in COVID-19-related mortality, the estimates reported
can be interpreted as the overall burden of mortality by ethnicity without accounting for
underlying testing patterns. We found a similar disparity in the overall burden of COVID-
19-related death in the full source population of approximately 6 million individuals in care at
the VA. However, when the model was restricted to individuals testing positive—which inher-
ently accounts for factors related to access to testing, non-random testing, and odds of infec-
tion—racial and ethnic disparities in mortality were no longer observed.
Policy implications
These findings underscore the urgent need to proactively tailor strategies to contain and pre-
vent further outbreaks in the US, principally focused on testing and getting individuals into
care. Black and Hispanic communities are at increased risk of infection, justifying increased
intensity of intervention. Our findings of variation in disparities over time and across geo-
graphic regions highlight the important need for community-based interventions at a state
and local level to contain further exposure and outbreaks of COVID-19, particularly tailored
to minority communities. Other interventions may include clinical decision support tools to
prompt educational and testing interventions based upon an individualized risk assessment of
testing positive for COVID-19. Outreach products about COVID-19 testing and disparities
should also be distributed to patient advocates and groups at all points of care.
Future research
We appeal to other researchers investigating racial and ethnic disparities to perform analyses
on the entire population at risk for COVID-19 where data are available, and to compare find-
ings associated at each stage in the clinical course of COVID-19, from testing to outcomes. In
this paper, we focused only on 30-day mortality among COVID-19 cases. We plan to explore
other outcomes, including hospitalization, intensive care, and intubation, in subsequent analy-
ses to examine whether racial and ethnic disparities exist in the clinical course of COVID-19
after testing positive and before death. Among other factors, future research should consider
the role of other social determinants of health, including employment type, number of individ-
uals in household, nursing home residence, and incarceration. Other racial and ethnic minori-
ties in the US deserve attention, and while we did not have enough statistical power to include
other groups in this analysis, we will continue to monitor these numbers for future research.
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